We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

US Supreme Court to consider availability of pre-emption defense for generic drug manufacturers

16 December 2010

On 13 December 2010 the United States Supreme Court granted certiorari in three consolidated cases to determine whether generic drug manufacturers can be held liable under state law for inadequate warnings where the product labels conform with the labels provided by the name brand manufacturers. This case is expected to have far-reaching implications for generic drug manufacturers and will test the limits of Wyeth v. Levine, 129 S. Ct. 1187 (2009), which held that failure-to-warn claims against name brand manufacturers are not preempted by the Food, Drug, and Cosmetic Act (FDCA).



Read "US Supreme Court to consider availability of pre-emption defense for generic drug manufacturers"

The team

Loading data